Enimmune corporation (TPEX:6564)
15.90
-0.55 (-3.34%)
Jun 13, 2025, 2:59 PM CST
Enimmune corporation Revenue
In the year 2024, Enimmune corporation had annual revenue of 39.92M TWD, down -8.23%. Enimmune corporation had revenue of 9.79M in the quarter ending December 31, 2024, a decrease of -35.76%.
Revenue
39.92M
Revenue Growth
-8.23%
P/S Ratio
29.82
Revenue / Employee
n/a
Employees
n/a
Market Cap
1.19B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 39.92M | -3.58M | -8.23% |
Dec 31, 2023 | 43.49M | -144.92M | -76.92% |
Dec 31, 2022 | 188.42M | 78.59M | 71.56% |
Dec 31, 2021 | 109.82M | 86.95M | 380.08% |
Dec 31, 2020 | 22.88M | 20.93M | 1,076.75% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
PharmaEssentia | 11.34B |
Caliway Biopharmaceuticals | 40.47M |
Bora Pharmaceuticals Co., LTD. | 20.87B |
Lotus Pharmaceutical | 19.12B |
Oneness Biotech | 117.33M |
Polaris Group | 87.67M |
Lumosa Therapeutics | 43.59M |
Center Laboratories | 1.63B |